skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

HT update: spotlight on estradiol/norethindrone acetate combination therapy

Review

(2877) Views  (530) Full article downloads

Authors: Colleen L Casey, Christine A Murray

Published Date March 2008 Volume 2008:3(1) Pages 9 - 16
DOI: http://dx.doi.org/10.2147/CIA.S1663

Colleen L Casey, Christine A Murray

University of Vermont, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Burlington, VT, USA

Abstract: The goal of postmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.

Keywords: postmenopausal hormone therapy, norethindrone acetate, estradiol








Readers of this article also read: